Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-61393215 Phase 1 SAD Study in Healthy Japanese Men
NCT04713930Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) and anxiety disorders comparing JNJ-61393215 with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events (AEs) up to 42 days and Plasma Concentration of JNJ-61393215. Started Jan 2021; status: completed.
02
Drugs
rocavorexant
03
Conditions
major depressive disorder (MDD)anxiety disorders
Beyond the preview
Go deeper on NCT04713930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713930.